Navoximod
Navoximod (GDC-0919; NLG- 919) is a potent IDO (indoleamine- (2,3) -dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
Product Specifications
CAS Number
1402837-78-8
Product Name Alternative
GDC-0919; NLG-919
UNSPSC
12352005
Hazard Statement
H315, H319
Target
Indoleamine 2,3-Dioxygenase (IDO)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Navoximod.html
Purity
99.99
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3
Molecular Formula
C18H21FN2O2
Molecular Weight
316.37
Precautions
H315, H319
References & Citations
[1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO) -pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.|[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.|[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
IDO
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![VEGFD Mouse Monoclonal Antibody [Clone ID: OTI1C7]](https://cdn.genprice.uk/products/937/68dd18b9061270361e9080da/imageurl/cf807516.webp)